Laurent Pharmaceuticals Inc.

Purpose

The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patients, and has a component allowing the transition to a new Phase 2 clinical development in mild-to-moderate non-hospitalized COVID-19 patients. LAU-7b is a next-generation COVID-19 antiviral that addresses the gap between early infection and critical COVID-19 disease, and aims for broad applicability at-home or in hospital. Because its host-directed mechanism, LAU-7b has the potential to work on all mutations of COVID-19, and other coronaviruses. Results from the Phase 2 pilot study showed 100% reduction in the risk of progression to mechanical ventilation and death in hospitalized moderate-to-severe patient.